Patent intelligence · US
US 10246508
Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines
Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines
Patent details — US 10246508
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 2, 2019
- Expiration
- Mar 28, 2039
- Applicant
- CHEMOMAB LTD.
- Claims
- 3
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61P
Quick answer
US 10246508 (Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines) is held by CHEMOMAB LTD.. Status: granted. Granted Apr 2, 2019. Expires Mar 28, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CHEMOMAB LTD.
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61P, A61P1/10, A61P11/00
More from CHEMOMAB LTD.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 10246508?
US 10246508 (Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines) is held by CHEMOMAB LTD.. Status: granted. Granted Apr 2, 2019. Expires Mar 28, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10246508?
CHEMOMAB LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 10246508 expire?
Our index shows an expiration date of Mar 28, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.